Topical Viral Vector Composition for Epidermolysis Bullosa Skin Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatment options for epidermolysis bullosa are invasive and do not effectively address the deficiencies in Collagen alpha-1 (VII) chain protein and Lysyl hydroxylase 3 protein, leading to fragile skin and severe complications.
Innovation Solution
A pharmaceutical composition comprising a virus vector encoding Collagen alpha-1 (VII) chain, Lysyl hydroxylase 3, or chimeric polypeptides, administered topically or transdermally, to enhance anchoring fibril formation and epithelial basement membrane organization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatment options are used for epidermolysis bullosa, then the treatment can be administered, but the treatment is invasive and does not effectively address the deficiencies in Collagen alpha-1 (VII) chain protein and Lysyl hydroxylase 3 protein
Solution Approach 1:
The patent uses a viral vector as an intermediary carrier to deliver the Collagen alpha-1 (VII) chain and Lysyl hydroxylase 3 protein directly to the target cells in the skin. This mediator approach allows the therapeutic proteins to be transported into the cells without requiring invasive surgical procedures, thereby resolving the contradiction between treatment effectiveness and invasiveness
Solution Approach 2:
The patent replaces invasive mechanical delivery methods (such as surgical implantation or injection) with a biological delivery system using viral vectors. The viral vectors naturally penetrate cell membranes and deliver the therapeutic cargo, substituting mechanical intrusion with a biochemical process that achieves the same therapeutic goal with minimal invasiveness
2Strength
If Collagen alpha-1 (VII) chain protein and Lysyl hydroxylase 3 protein are delivered to address the deficiencies, then the anchoring fibril formation and epithelial basement membrane organization can be enhanced, but the delivery method must be non-invasive or minimally invasive
Solution Approach 1:
The viral vector serves as a mediator that transports the Collagen alpha-1 (VII) chain and Lysyl hydroxylase 3 protein into the target cells. This intermediary approach enables the enhancement of anchoring fibril formation without requiring invasive delivery methods, as the viral vector naturally enters cells through endocytosis or membrane fusion
Solution Approach 2:
The patent changes the delivery parameter from invasive mechanical insertion to non-invasive viral-mediated delivery. By altering the administration method from surgical to biochemical, the patent achieves enhanced anchoring fibril formation while maintaining minimal invasiveness
Data Source
AI summary
Provided herein are pharmaceutical compositions comprising one or more polynucleotides suitable for enhancing, increasing, augmenting, and/or supplementing the levels of Collagen alpha-1 (VII) chain polypeptide and/or Lysyl hydroxylase 3 polypeptide and/or Keratin type I cytoskeletal 17 polypeptide in a subject. Also provided herein are pharmaceutical compositions and methods of use for providing prophylactic, palliative, or therapeutic relief of a wound, disorder, or disease of the skin in a subject, including a subject having, or at risk of developing, one or more symptoms of epidermolysis bullosa.